Form 4: 10x Genomics Director Alan Mateo Granted Over 15,000 Restricted Stock Units

Alan Mateo, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.

Summary

• Alan Mateo, a Director of 10x Genomics, Inc. (TXG), acquired 15,357 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 3, 2025.
• The acquisition price for these RSUs was $0, indicating they were a grant rather than a purchase.
• Following this transaction, Alan Mateo beneficially owns a total of 77,048 shares of Class A Common Stock directly.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs are scheduled to vest in quarterly installments, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, contingent upon Mr. Mateo's continued service as a provider.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is generally a positive signal as it aligns management's interests with shareholders. It's a routine compensation event, so the positive impact is moderate rather than significant.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Alan Mateo aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• RSU grants are a common form of equity compensation, indicating standard corporate governance practices for executive and director incentives.

Future Outlook

The granted Restricted Stock Units (RSUs) will vest in quarterly installments starting from May 21, 2025, contingent on the director's continued service, which will result in the issuance of Class A Common Stock over time.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common across publicly traded companies as part of their executive and director compensation programs. Such grants are standard practice in the biotechnology and life sciences tools industry, where attracting and retaining top talent often involves significant equity incentives.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as compensation is a widely adopted practice across the technology and life sciences sectors, including companies comparable to 10x Genomics such as Illumina (ILMN) or Pacific Biosciences (PACB), which also utilize equity-based incentives to align management interests with shareholder value.
• The vesting schedule of 1/4th quarterly from a specific date is a common structure for RSU grants, designed to encourage long-term commitment and retention, consistent with industry benchmarks for director compensation.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of Restricted Stock Units (RSUs) from 10x Genomics, Inc. to Alan Mateo, a Director of the company. This is a standard insider compensation arrangement.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the RSUs gain value if the stock price increases.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The vesting of 1/4th of the 15,357 Restricted Stock Units on each quarterly anniversary measured from May 21, 2025, subject to Alan Mateo's continued service.

Key Dates

Keywords

10x Genomics, TXG, Alan Mateo, Restricted Stock Units, RSU, Insider Transaction, Form 4, SEC Filing, Equity Compensation, Director Compensation